BACKGROUND: Adding oral clodronate to postoperative adjuvant breast cancer therapy significantly improves disease-free survival (DFS) and overall survival (OS). Long-term follow-up data from the prospective, randomized, controlled study are reported. PATIENTS AND METHODS: Patients with primary breast cancer received clodronate 1600 mg/day for 2 years or no treatment along with standard adjuvant breast cancer treatment. RESULTS: Analysis of 290 of 302 patients demonstrated that a significant improvement in OS was maintained in the clodronate group at a median follow-up of 103 +/- 12 months; 20.4% of patients in the clodronate group versus 40.7% of control group patients (P = 0.04) died during the 8.5 years following primary surgical therapy. Significant reductions in the incidence of bony and visceral metastases and improvement in duration of DFS at 36- and 55-month follow-up periods were no longer seen with clodronate. CONCLUSION: These long-term survival data extend the survival advantage reported in previous studies with oral clodronate in breast cancer.
RCT Entities:
BACKGROUND: Adding oral clodronate to postoperative adjuvant breast cancer therapy significantly improves disease-free survival (DFS) and overall survival (OS). Long-term follow-up data from the prospective, randomized, controlled study are reported. PATIENTS AND METHODS: Patients with primary breast cancer received clodronate 1600 mg/day for 2 years or no treatment along with standard adjuvant breast cancer treatment. RESULTS: Analysis of 290 of 302 patients demonstrated that a significant improvement in OS was maintained in the clodronate group at a median follow-up of 103 +/- 12 months; 20.4% of patients in the clodronate group versus 40.7% of control group patients (P = 0.04) died during the 8.5 years following primary surgical therapy. Significant reductions in the incidence of bony and visceral metastases and improvement in duration of DFS at 36- and 55-month follow-up periods were no longer seen with clodronate. CONCLUSION: These long-term survival data extend the survival advantage reported in previous studies with oral clodronate in breast cancer.
Authors: S Boissier; M Ferreras; O Peyruchaud; S Magnetto; F H Ebetino; M Colombel; P Delmas; J M Delaissé; P Clézardin Journal: Cancer Res Date: 2000-06-01 Impact factor: 12.701
Authors: Trevor Powles; Sandy Paterson; John A Kanis; Eugene McCloskey; Sue Ashley; Alwynne Tidy; Kirsi Rosenqvist; Ian Smith; Lars Ottestad; Sandra Legault; Marjo Pajunen; Auli Nevantaus; Esa Männistö; Anne Suovuori; Sari Atula; Jaakko Nevalainen; Liisa Pylkkänen Journal: J Clin Oncol Date: 2002-08-01 Impact factor: 44.544
Authors: Trevor Powles; Alexander Paterson; Eugene McCloskey; Phil Schein; Bobbi Scheffler; Alwynne Tidy; Sue Ashley; Ian Smith; Lars Ottestad; John Kanis Journal: Breast Cancer Res Date: 2006-03-15 Impact factor: 6.466
Authors: Naoki Niikura; Jun Liu; Naoki Hayashi; Shana L Palla; Yutaka Tokuda; Gabriel N Hortobagyi; Naoto T Ueno; Richard L Theriault Journal: Cancer Date: 2011-12-02 Impact factor: 6.860
Authors: Laura Biganzoli; Hervé Bonnefoi; Fatima Cardoso; Robert Coleman; Beat Thürlimann Journal: Breast Care (Basel) Date: 2009-08-14 Impact factor: 2.860
Authors: Brent O'Carrigan; Matthew Hf Wong; Melina L Willson; Martin R Stockler; Nick Pavlakis; Annabel Goodwin Journal: Cochrane Database Syst Rev Date: 2017-10-30
Authors: J D Veltman; M E H Lambers; M van Nimwegen; R W Hendriks; H C Hoogsteden; J P J J Hegmans; J G J V Aerts Journal: Br J Cancer Date: 2010-07-27 Impact factor: 7.640
Authors: T R Cawthorn; E Amir; R Broom; O Freedman; D Gianfelice; D Barth; D Wang; I Holen; S J Done; M Clemons Journal: Clin Exp Metastasis Date: 2009-08-21 Impact factor: 5.150